ClinicalTrials.gg
Status unknownNCT01329003Updated Apr 5, 2011

DNA-damage Pathways in Workers Exposed to Silica (Caesar Stone)

An observational study in Silicosis, sponsored by Tel-Aviv Sourasky Medical Center. Status unknown at 1 site in Israel. Open to male participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-04-05.

Sponsored by Tel-Aviv Sourasky Medical Center · Observational

The sponsor has not verified this record recently (last verified Mar 2011), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Time perspective
Cross-sectional
Enrollment
150
Ages
18 Years to 70 Years
Sex
Male
01

Study summary

Silicosis is well-known occupational disease caused by free crystalline silica (silicon dioxide) and is marked by inflammation and pulmonary fibrosis. There are cumulative evidences that exposure to Caesar stone (quartz surface products that manufactured from up to 93% quartz, polymer resins and pigments) is particularly dangerous to exposed workers.

Goals: To examine correlation between disease and exposure to Caesar stone and genetic differences regarding genes involved in oxidative stress to understand Genetic susceptibility

Read the detailed description

It is a sub-study of "DNA-damage biomarkers to monitor and early detect health impairment in workers exposed to Silica (Caesar Stone)" study. Study participants would be recruited during two years of the study. They will be asked to come to a single visit at Pulmonary Laboratory of Tel Aviv Medical Center. During the meeting, participants will be given a precise explanation about the tests they will perform and after signing the informed consent will perform following tests:

  1. Induced sputum (IS)
  2. Exhaled Breath Condensate
  3. Pulmonary function tests (PFTs)
  4. Participants will be asked to complete occupational questionnaire

Genetic studies (DNA) will be done from peripheral blood samples (20 ml) to study differences in Heme oxygenase 1 (HO-1) gene sequencing between participants with evidences of clinically definite silicosis according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines and participants without evidences of clinically definite silicosis.DNA samples will be obtained and coded in the same day of a participant visit and after collecting reasonable amount of samples examination of genes of interest will be done.Analysis of data will be done after the completion of data collection and laboratory tests.

Each sample will be given specific code to protect confidentiality of participants. Blood samples, test results and the code key will be kept in different places and only few research staff will have the accessibility to genetic information. In any case employers or any other persons that not included in research staff will not have any accessibility to this information. In this study genetic analysis is not connected to gender, nationality or any other social feature.

02

Conditions studied

  • Silicosis

Browse trials for

Keywords

  • Silicosis
03

In context

Silicosis

20 studies on the registry are indexed under Silicosis; 3 are open to participants now.

This study's planned enrollment of 150 is close to the median of 150 across 11 observational studies indexed under Silicosis.

Browse Silicosis studies →

Lead sponsor

Tel-Aviv Sourasky Medical Center is the lead sponsor of 554 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

At least six months of occupational exposure to Caesar stone

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. male
  2. 18-70 years old
  3. At least six months of professional exposure to Caesar stone

Exclusion criteria

Exclusion Criteria:

  1. Other occupational exposure (welding of any kind)
  2. (COPD), tuberculosis, asthma, disease in healthy exposed workers
  3. Interstitial lung disease in exposed workers with clinically approved silicosis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Time perspective
Cross-sectional
Enrollment
150 participants (estimated)
Biospecimen retention
Samples with dna

Groups and cohorts

  • exposed workers

    At least six months of occupational exposure to Caesar stone

06

What researchers measure

Primary outcomes

  1. Evidence of clinically definite silicosis according to American Thoracic Society/European Respiratory Society (ATS/ERS)guidelines

    1. Occupational physician examination 2. Pulmonary function tests (PFTs): The measurement will be performed using standard protocols according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines. Including Lung diffusion testing 3. Computed Tomography (CT) test if need

    Time frame: one day

Secondary outcomes

  1. Differences in Heme oxygenase 1 (HO-1) gene sequencing

    Genetic studies (DNA) will be done from peripheral blood samples (20 ml) to study differences in Heme oxygenase 1 (HO-1) gene sequencing between participants with evidences of clinically definite silicosis according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines and participants without evidences of clinically definite silicosis

    Time frame: one day

07

Study locations

1 site
  • Pulmonary Laboratory of Tel Aviv Sourasky Medical Center
    Tel Aviv, Israel
    • Daria Bliznuk, BSc · Contactdasha_bl@yahoo.com · 972-0506353669
    • Elizabeth Fierman, professor · Contactlizif@tasmc.health.gov.il · 972-3-6973988
    • Elizabeth Fierman, professor · Sub investigator
    • Yehuda Shwartz, MD · Principal investigator
    • Mordehai Kremer, professor · Sub investigator
    • Daria Bliznuk, BSc · Sub investigator
    • Irina Golov, Ms · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2011
First posted
Apr 5, 2011
Start
Sep 2011
Primary completionEst.
Sep 2013
CompletionEst.
Sep 2013
Last update
Apr 5, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01329003
First posted
Apr 5, 2011
Start date
Sep 2011
Primary completion
Sep 2013 (estimated)
Completion
Sep 2013 (estimated)
Last update
Apr 5, 2011

Study contacts

Daria Bliznuk, BSc
Contact
dasha_bl@yahoo.com
972-0506353669
Elizabeth Fairman, professor
Contact
lizif@tasmc.health.gov.il
972-3-6973988
Yehuda Shwartz, MD
principal investigator · Tel Aviv medical center. Pulmonary and Allergy department

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion